Ascendis Pharma CFO buys 100 shares in open trade

Ascendis Pharma A/S EVP & Chief Financial Officer Scott Thomas Smith made an open-market purchase of 100 Ordinary Shares on June 2, 2026 at $219.00 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ascendis Pharma A/S EVP & Chief Financial Officer Scott Thomas Smith made an open-market purchase of 100 Ordinary Shares on June 2, 2026 at $219.00 per share.

Following this transaction, he directly holds 4,367 Ordinary Shares of Ascendis Pharma A/S.

Insider Trade Summary

Net Buyer: 100 shares

Net Buy 1 txn

Insider SMITH SCOTT THOMAS

Role EVP & Chief Financial Officer

Bought 100 shs ($22K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	100	$219.00	$22K

Holdings After Transaction: Ordinary Shares — 4,367 shares (Direct)

Key Figures

Shares purchased: 100 Ordinary Shares Purchase price: $219.00 per share Shares held after transaction: 4,367 Ordinary Shares

3 metrics

Shares purchased 100 Ordinary Shares Open-market purchase on June 2, 2026

Purchase price $219.00 per share Price for Ordinary Shares bought in the transaction

Shares held after transaction 4,367 Ordinary Shares Direct ownership after June 2, 2026 purchase

Key Terms

open-market purchase, Ordinary Shares, Form 4

3 terms

open-market purchase financial

"made an open-market purchase of 100 Ordinary Shares on June 2, 2026"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Ordinary Shares financial

"made an open-market purchase of 100 Ordinary Shares on June 2, 2026"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 regulatory

"This was an open-market transaction reported on a Form 4 insider filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ascendis Pharma (ASND) report for its CFO?

Ascendis Pharma reported that EVP & Chief Financial Officer Scott Thomas Smith bought 100 Ordinary Shares in an open-market transaction. The purchase occurred on June 2, 2026 at a price of $219.00 per share, increasing his direct holdings.

How many Ascendis Pharma (ASND) shares did the CFO buy and at what price?

The CFO purchased 100 Ordinary Shares of Ascendis Pharma at $219.00 per share. This was an open-market transaction reported on a Form 4 insider filing and reflects a direct ownership increase.

What are the CFO’s total Ascendis Pharma (ASND) holdings after this transaction?

After the reported open-market purchase, the CFO directly owns 4,367 Ordinary Shares of Ascendis Pharma. This total includes the additional 100 shares bought on June 2, 2026 at $219.00 per share.

Was the Ascendis Pharma (ASND) CFO transaction a buy or a sell?

The transaction was a buy. The Form 4 shows an open-market purchase of 100 Ordinary Shares by the CFO on June 2, 2026, coded as a purchase at a price of $219.00 per share.

What does the transaction code on the Ascendis Pharma (ASND) Form 4 mean?

The Form 4 uses transaction code “P,” which indicates a purchase in an open market or private transaction. In this case, it reflects the CFO’s acquisition of 100 Ordinary Shares at $219.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/02/2026 - 04:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH SCOTT THOMAS

(Last)

(First)

(Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP

DK-2900

(City)

(State)

(Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/02/2026		P		100	A	$219	4,367	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Michael Wolff Jensen as attorney-in-fact for Scott Smith	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR